Amgen

Open: 305.24 Close: 306.51 Change: 1.27

Try an AI to get informed about investing in Amgen.

Are looking for the most relevant information about Amgen? Investor spend a lot of time searching for information to make investment decisions in Amgen. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, earnings, obesity, weight, loss, NVIDIA, use, and the most common words in the summary are: amgen, market, best, stock, credit, news, company, . One of the sentences in the summary was: Amgen is expected to release next earnings on 02/06/2024 with an earnings per share …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

Amgen is expected to release next earnings on 02/06/2024 with an earnings per share estimate of $4.60. Amgen shares were roughly flat in morning trading.

Today's News

Amgen has a pipeline of “a half dozen or so” obesity candidates that are “rapidly advancing” The drugmaker hopes studies will prove that the two interventions together can provide quicker and more effective weight loss and possibly better weight loss maintenance. In March 2023, NVIDIA announced that Amgen was one of the first companies to employ NVIDIA BioNeMo, which researchers have used to build generative AI models. Amgen Inc. is an Equal Opportunity Employer and will consider all qualified applicants for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, protected veteran status or disability status. Amgen is expected to release next earnings on 02/06/2024 with an earnings per share estimate of $4.60. Amgen offers a Total Rewards Plan comprising health and welfare plans for staff and eligible dependents. Amgen shares were roughly flat in morning trading. Chicago-based Xeris said Wednesday morning that Amgen would develop, manufacture and commercialize a subcutaneous formulation of teprotumumab to treat Thyroid Eye Disease. Xeris may get up to $75 million in development and regulatory milestones. Amgen, Inc. (AMGN) Recent price action has pushed AMGN to a new swing high, completing a classic cup and handle pattern. Amgen spotlights obesity prospects. CEO: 2024 looks to be a busy year for Amgen. Amgen (amgn) suffers a larger drop than the general market: key insights. The upcoming earnings release of Amgen will be of great interest. US Patent Office Offers Guidance on Enablement After Amgen-Sanofi. US Patent and Trademark Office employees will continue using the same factors to determine whether applications meet patent laws “enablement” requirement.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

This document will help you to evaluate Amgen without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, earnings, obesity, weight, loss, NVIDIA, use, and the most common words in the summary are: amgen, market, best, stock, credit, news, company, . One of the sentences in the summary was: Amgen is expected to release next earnings on 02/06/2024 with an earnings per share estimate of $4.60. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #market #best #stock #credit #news #company.